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  23 
ABSTRACT 24 
Botulinum neurotoxin serotype A1 (BoNT/A1) is well adapted to invade motoneurons. Here we 25 
report a 2.0 Å resolution crystal structure of BoNT/A1 receptor-binding domain in complex with 26 
its neuronal receptor, the glycosylated human SV2C. We find that the remarkable neuronal 27 
tropism of BoNT/A1 is only achieved by directly recognizing both the peptide moiety and an N-28 
linked glycan on SV2. This N-glycan—conserved in all SV2 isoforms across vertebrates—is 29 
essential for BoNT/A1 binding to neurons and its potent neurotoxicity. Remarkably, the glycan-30 
binding interface is largely conserved in a newly identified mosaic toxin BoNT/HA (also known 31 
as mosaic BoNT/FA), and it is also the targeting site for a potent human BoNT/A1-neutralizing 32 
antibody that is currently licensed as an anti-botulism drug. Collectively, our studies reveal a 33 
new paradigm of host-pathogen interactions, in which pathogens exploit conserved host post-34 
translational modifications to achieve highly specific receptor binding while also tolerating 35 
genetic changes across multiple isoforms of receptors.  36 
BoNT/A1 is one of the most dangerous potential bioterrorism agents. Ironically, it is a licensed 37 
drug widely used in treating a variety of medical and cosmetic conditions 1. According to a well-38 
accepted dual-receptor model, the extreme potency of BoNT/A1 targeting motoneurons is 39 
mediated by its receptor-binding domain (HCA), which synergistically binds to host protein 40 
receptors and gangliosides on the neuronal surface at neuromuscular junctions 2-4. The synaptic 41 
vesicle glycoprotein 2 (SV2), a family of 12-transmembrane domain proteins that have three 42 
isoforms (SV2A, 2B, and 2C) in humans, are protein receptors for BoNT/A1 5,6, as well as for 43 
BoNT/E 7, BoNT/D 8, and BoNT/F 9,10.  44 
We have previously mapped the BoNT/A1-binding site to the fourth luminal domain of SV2s 45 
(SV2-L4) 5,6. A crystal structure of HCA in complex with the recombinant human SV2C-L4 46 
expressed in E. coli (referred to as bSV2C with b indicating bacterial expression) has been 47 
reported recently 11. It shows that HCA-bSV2C recognition relies mostly on backbone-to-48 
backbone interactions within a small interface (~596 Å2), mediated by two β-strands in HCA and 49 
one open edge of the quadrilateral β-helices of bSV2C 11. This binding mode is in sharp contrast 50 
to BoNT/B, which recognizes its receptors synaptotagmin-I/II (Syt-I/II) through an extensive 51 
side-chain mediated protein-protein interaction network that ensures high binding affinity and 52 
specificity towards Syt-I/II 12,13. So, how could BoNT/A1 possibly achieve extreme efficacy of 53 
targeting neurons using mostly backbone-mediated interactions for receptor recognition?  54 
In this study, we determined the crystal structures of HCA in complex with rat bSV2C-L4 and the 55 
physiologically more relevant glycosylated human SV2C-L4. We found that BoNT/A1 56 
recognizes two distinct structural elements on SV2C: the protein moiety and an N-linked glycan 57 
that is conserved in all known SV2 homologs across vertebrates. Further biophysical, cellular 58 
and functional studies demonstrate that SV2 glycans are essential for BoNT/A1 binding to 59 
neuron and its extreme toxicity at its physiological site of action, the motor nerve terminals. 60 
Moreover, we found that the glycan-binding site of BoNT/A1 is also the target of a potent human 61 
neutralizing antibody, suggesting the potential for SV2 glycan as a novel target for developing 62 
BoNT inhibitors. 63 
 64 
RESULTS 65 
The crystal structure of HCA in complex with rat bSV2C 66 
Amino acid sequence analyses showed that even the few residues that mediate side-chain 67 
interactions in the HCA and human bSV2C complex are not strictly conserved in SV2A and 68 
SV2B, or even SV2C from other species (e.g. rodents) (Supplementary Fig. 1). To gain a better 69 
insight into how BoNT/A1 can recognize SV2C from different species, we determined the 70 
crystal structure of HCA in complex with rat SV2C-L4 expressed in E. coli (Table 1). The 71 
structure of the rat bSV2C-HCA complex is virtually identical to that of the human bSV2C 72 
complex [root mean square deviation (RMSD) ~ 0.70 Å over 496 aligned Cα pairs]. Two major 73 
differences are observed. First, HCA-R1294 forms hydrogen bonds with S519, C520, T521, and 74 
D539 of rat bSV2C (Supplementary Fig. 2), which are not observed in the structure of the 75 
human bSV2C-HCA complex probably due to the different crystal packing modes 11. 76 
Interestingly, R1294 only exists in two of the eight BoNT/A subtypes currently known 77 
(BoNT/A1 and A4). Second, a cation-π stacking interaction between BoNT/A1-R1156—78 
exclusively existing in subtype BoNT/A1—and human SV2C-F563, previously thought to be 79 
critical for BoNT/A1-SV2C recognition 11, does not exist in the rat bSV2C-HCA complex 80 
because rat SV2C has a leucine (L563) in the place of human SV2C-F563. Leucine is also the 81 
homologous residue on SV2A and SV2B in both humans and rodents (Supplementary Fig. 1c). 82 
These findings suggest that the side-chain mediated interactions may vary significantly among 83 
different BoNT/A subtypes and SV2 isoforms, thus unlikely provide sufficient binding 84 
specificity and affinity between them. Therefore, some crucial BoNT/A1-SV2 interactions are 85 
missing in the crystal structures of HCA-bSV2C complexes described here and previously 11. 86 
 87 
SV2 glycosylation is crucial for BoNT/A1 binding to neurons 88 
Native SV2s are glycosylated in neurons 14, and one of the three N-linked glycosylation motifs in 89 
L4—conserved in all SV2 isoforms across vertebrates—is located at the center of the BoNT/A1-90 
binding interface of SV2 (e.g. N573 in SV2A, N516 in SV2B, and N559 in SV2C for human) 91 
(Supplementary Fig. 1c). To explore the functional role of this N-linked glycan, we utilized a 92 
molecule replacement approach to express either wild type (WT) SV2A-C, or the corresponding 93 
deglycosylation mutants (SV2A-N573A, SV2B-N516A, and SV2C-N559A) in 94 
hippocampal/cortical neurons cultured from SV2A/SV2B double knockout (KO) mice. Most 95 
hippocampal/cortical neurons do not express SV2C 14, and thus these neurons cultured from 96 
SV2A/SV2B double KO mice serve as a SV2-null neuron model. These deglycosylation 97 
mutations of SV2 do not affect protein-protein interactions with BoNT/A1, as e.g. bSV2C-98 
N559A maintained a WT-like binding to HCA 11. 99 
The deglycosylation mutants of SV2A, 2B, and 2C all showed a lower molecular weight 100 
compared to WT SV2s, confirming that this Asn residue is indeed glycosylated in neurons (Fig. 101 
1 and Supplementary Fig. 3). The expression level of SV2A-N573A was comparable to the 102 
WT SV2A, but there is a drastic reduction of SV2B-N516A expression and a mild reduction of 103 
SV2C-N559A expression (Supplementary Fig. 3). It suggests that glycosylation at this site is 104 
crucial for folding and/or stability of SV2B and to a lesser degree for SV2C—a known function 105 
of N-linked glycans 15.  106 
We thus focused on SV2A-N573A and SV2C-N559A, and examined SV2-mediated toxin entry 107 
for BoNT/A1 and BoNT/D by analyzing the cleavage of synaptosomal-associated protein of 25 108 
kDa (SNAP-25, the substrate of BoNT/A1) and synaptobrevin/vesicle-associated membrane 109 
protein 2 (VAMP2, the substrate of BoNT/D) after toxin exposure. BoNT/D serves here as an 110 
internal control for regular trafficking and sorting of SV2 mutants, as BoNT/D uses SV2s as 111 
receptors independent to N-glycosylation 8. Furthermore, we have previously shown that 112 
BoNT/B1 that does not use SV2 as its receptor binds and enters the WT and SV2 KO neurons at 113 
similar levels 5,7. We found that the SV2 KO neurons did not show BoNT/A1 entry at the 114 
conditions tested, which is likely due to BoNT/A1’s low affinity for the ganglioside receptor that 115 
is unable to allow cell entry in the absence of SV2 16,17. Expression of SV2A-N573A and SV2C-116 
N559A mediated significantly less entry of BoNT/A1 compared to the WT SV2s, whereas 117 
BoNT/D entry was not affected (Fig. 1). These results suggest that SV2 glycosylation at this 118 
strictly conserved site clearly contributes to BoNT/A1 binding and entry into neurons.  119 
 120 
The SV2C glycans significantly enhances HCA binding 121 
Glycosylation is a common and highly diverse post-translational protein modification that 122 
profoundly alters the protein behavior 15. Do the N-glycans contribute directly to BoNT/A1 123 
binding? In this regard, we first carried out surface plasmon resonance (SPR) to examine how 124 
HCA binds to the human bSV2C. We found that the binding displays a fast association rate (ka: 125 
1.5 × 106 M-1s-1) and a fast dissociation rate (kd: 0.11 s-1) (Fig. 2a), and the overall dissociation 126 
constant (KD) of ~86 nM was comparable to a previously reported KD of 260 nM determined by 127 
fluorescence anisotropy experiment 11. The nature of this transient interaction is consistent with 128 
the pattern of backbone-to-backbone interactions revealed in the crystal structure, but difficult to 129 
reconcile with the extreme specificity of BoNT/A1 toward neurons. 130 
We then expressed the human SV2C-L4 (residues V473-T567) as a secreted protein using 131 
human embryonic kidney 293 cells (HEK293), to mimic the physiologically relevant 132 
glycosylated receptor. HEK293 cells have been widely used to produce glycoproteins with 133 
human glycosylation patters 18. The resulting protein (referred to as gSV2C, g stands for 134 
glycosylation) is glycosylated as evidenced by the appearance of multiple bands on SDS-PAGE 135 
that are bigger than its peptide mass and represent heterogeneous glycoforms. We characterized 136 
binding of HCA to gSV2C by SPR, which revealed two binding components (Fig. 2b-c and 137 
Supplementary Fig. 4). A transient low affinity binding (KD ~220 nM) closely resembles the 138 
binding of HCA to bSV2C, which is likely due to heterogeneous glycosylation of SV2C under 139 
over-expression conditions 19. Notably, a high affinity binding (KD ~15 nM) of gSV2C displays a 140 
~22-fold slower dissociation rate and a ~4-fold slower association rate compared to bSV2C. The 141 
slightly decreased association rate of gSV2C likely stems from restricted carbohydrate flexibility 142 
upon toxin binding, a physiological event that BoNT/A1 will encounter in vivo because the 143 
neuronal SV2s are glycosylated. Therefore, the relatively fast association rate displayed by 144 
bSV2C artificially increases the binding affinity of bSV2C. Taken together, these data 145 
demonstrate that the glycans of gSV2C stabilize the HCA-gSV2C complex by significantly 146 
decreasing the dissociation rate. 147 
 148 
The crystal structure of HCA in complex with the glycosylated human SV2C 149 
We next determined the crystal structure of HCA in complex with gSV2C at 2.0 Å resolution 150 
(Table 1). The overall architecture of the HCA-gSV2C complex is similar to that of the bSV2C 151 
complex (RMSD ~0.88 Å over 489 aligned Cα pairs). A complex-type N-linked glycan attached 152 
to gSV2C-N559 was observed with clear electron densities for the quadruple-saccharide core 153 
made up of two N-acetylglucosamine (NAG), a mannose (BMA), and a fucose (FUC) (Fig. 3 154 
and Supplementary Fig. 5). There are two other putative N-linked glycosylation sites (N484 155 
and N534) that are localized on SV2C-L4 and also conserved on SV2A and SV2B 156 
(Supplementary Fig. 1c). Only one NAG could be resolved in the electron density for the N534 157 
glycan likely due to its high mobility, whereas no sugar could be identified at N484. SV2C N484 158 
and N534 are located far away from BoNT/A1-binding interface, and thus unlikely to directly 159 
participate in toxin binding.  160 
Remarkably the N559-glycan directly interacts with HCA through a network of hydrogen bonds 161 
and van der Waals contacts. The most prominent are stacking interactions between residues F953 162 
and H1064 of HCA and the hydrophobic faces of the two NAG. In addition, ten well-defined 163 
water molecules act as a molecular “glue” in the glycan-HCA interface to further strengthen the 164 
interactions (Fig. 3d-e and Supplementary Table 1). These interactions almost double the 165 
contact area between HCA and SV2C from 557 to 925 Å2. There are also weak electron densities 166 
beyond the mannose, suggesting that there might be more extensive HCA-glycan interactions that 167 
were not resolved, possibly due to the inherent flexibility of glycans and heterogeneous 168 
glycosylation. This structure unambiguously reveals that the N559-glycan of SV2C is recognized 169 
directly by BoNT/A1 as an integral part of the toxin-binding site. 170 
 171 
BoNT/A1-glycan binding is conserved across SV2 isoforms and is critical for BoNT/A1 172 
binding to neurons 173 
We then sought to understand the functional role of protein-glycan interactions in BoNT/A1-SV2 174 
recognition. Based on the crystal structure, we designed a set of single-site mutations on HCA 175 
that selectively disrupt glycan binding: F953G and H1064G abolish the critical stacking of 176 
aromatic side chains against the sugar rings, and F953R, H1064R, G1292Q, and G1292R cause 177 
clashes between their bulky side chains and the N559-glycan. None of these mutations affected 178 
HCA folding and stability as verified by thermal denaturation experiments, nor did they affect 179 
HCA binding to bSV2C based on pull-down and SPR studies. As expected, these mutants 180 
markedly decreased HCA binding to gSV2C, strongly supporting the direct involvement of 181 
N559-glycan of SV2C in BoNT/A1 binding (Supplementary Figs. 6 and 7a-c). Interestingly, 182 
SPR studies showed that the glycan-binding deficient HCA-F953G binds to gSV2C much weaker 183 
than bSV2C (KD: ~760 nM vs. ~160 nM) (Supplementary Fig. 7d-f). Therefore, the native 184 
neuronal SV2s that are always glycosylated initially impose steric hindrances for BoNT/A1 185 
recognition. But BoNT/A1 manages to overcome this obstacle by directly employing SV2 186 
glycans to strengthen binding. 187 
We examined how these HCA mutants bind to native SV2s in neurons. First, we analyzed 188 
binding of HCA to endogenous SV2A and SV2B using cultured rat hippocampal/cortical neuron 189 
14 (Fig. 4a-b). Mutations F953G, F953R, G1292Q, and G1292R largely abolished binding of 190 
HCA to neurons; H1064G and H1064R also drastically reduced binding, suggesting that protein-191 
glycan interactions are essential for BoNT/A1 binding to native SV2s on neurons. We further 192 
examined neurons that exclusively expressed SV2A, 2B, or 2C: hippocampal/cortical neurons 193 
cultured from SV2A(+/+)SV2B(-/-) mice served as neurons that only express SV2A, and 194 
neurons that only express SV2B or SV2C were created by infecting neurons cultured from 195 
SV2A(-/-)SV2B(-/-) mice with lentiviruses that express SV2B or SV2C, respectively. Mutating 196 
glycan-binding residues on HCA (e.g. F953G, G1292R, and H1064G) reduced HCA binding in 197 
all cases tested, demonstrating that BoNT/A1-glycan interactions are conserved and essential for 198 
all three SV2 isoforms (Fig. 4c-e and Supplementary Fig. 8). 199 
 200 
The conserved SV2 N-glycan allows to tolerate genetic changes on various BoNT/A 201 
subtypes 202 
Complementing our studies on protein-glycan interactions, we also examine the contribution of 203 
side-chain-mediated protein-protein interactions to SV2 recognition that could vary significantly 204 
among the eight different BoNT/A subtypes (Supplementary Fig. 9). In this regard, residues 205 
R1156 and R1294 of BoNT/A1 were mutated to their counterparts in other BoNT/A subtypes 206 
(e.g. R1156E and R1294S), which disrupt their interactions with the peptide moiety of SV2C but 207 
without affecting glycan binding. We used the double mutant HCA-T1145A-T1146A as a control 208 
11. These two Thr residues, located at the core of protein-protein interface, are conserved in all 209 
BoNT/A subtypes (Supplementary Fig. 9). We found that binding of HCA-T1145A-T1146A to 210 
cultured rat hippocampal/cortical neurons was abolished (Fig. 4a-b). This is consistent with an 211 
earlier study showing that HCA-T1145A-T1146A can no longer bind to bSV2C 11. Interestingly, 212 
we found that HCA-R1156E and R1294S still bound significantly to neurons (Fig. 4a-b), even 213 
though they showed decreased binding to both human bSV2C and gSV2C in vitro 214 
(Supplementary Fig. 7). These data suggest that loss of side-chain-mediated interactions at 215 
R1156 and R1294 of BoNT/A1 is tolerated on neuronal surfaces likely due to the presence of 216 
SV2 glycan and co-receptor gangliosides.  217 
 218 
SV2 glycan-binding is essential for the extreme potency of BoNT/A1 at motor nerve 219 
terminals 220 
To further establish the physiological relevance of protein-glycan interactions, we produced full-221 
length BoNT/A1 containing single-site glycan-binding deficient mutations (F953G, F953R, 222 
H1064G, H1064R, G1292V, or G1292R) and examined their neurotoxicity at motor nerve 223 
terminals using an ex vivo mouse phrenic nerve hemi-diaphragm (MPN) assay (Fig. 5) 20. 224 
Remarkably, all these mutations drastically reduced the potency of BoNT/A1. BoNT/A1-F953R 225 
had no detectable toxicity even at the maximal concentration tested (200 nM), which reflects a 226 
larger than 106-fold of toxicity reduction even though it displayed fully functional Zn2+-227 
endoprotease activity in vitro. Mutation G1292R also severely reduced the toxicity by 350-fold 228 
21. Mutations H1064G and H1064R displayed 3- and 7-fold reduction, respectively. These data 229 
demonstrate that glycan-binding is essential for the extreme potency of BoNT/A1 at the motor 230 
nerve terminals, its physiological site of action. 231 
 232 
The SV2 glycan-binding mode is conserved in the newly identified BoNT/HA 233 
We next examined whether glycan binding is conserved in natural variants of BoNT/A1, as 234 
BoNT genes are actively evolved and at least 40 different subtypes of BoNT have been reported 235 
1. In this regard, we focused on a newly reported mosaic toxin type HA (BoNT/HA, also known 236 
as BoNT/FA), which has a hybrid-like structure including a BoNT/A1-like HC 22-26. HCHA is 237 
highly similar to HCA (~83% identical) (Supplementary Fig. 9). Sequence alignment revealed 238 
that most of the glycan-binding residues, such as F953 and H1064, are conserved in HCA and 239 
HCHA, but residues R1156 and R1294 of HCA are changed to M1148 and S1286 in HCHA. 240 
HCHA showed much weaker binding to human bSV2C as compared to HCA, whereas its binding 241 
to human gSV2C was comparable to that of HCA (Fig. 6a). It suggests that the loss of side-chain 242 
interactions due to genetic changes of M1148 and S1286 in HCHA is compensated by SV2C 243 
glycan. In contrast, HCHA-F943G (equivalent to HCA-F953G) failed to bind to gSV2C based on 244 
a pull-down assay, nor did it bind to cortical neurons, likely due to the disruption of glycan 245 
binding (Fig. 6a-b). These data confirm that a similar glycan-binding mode is conserved in 246 
HCHA and is critical for its binding to SV2s on neurons.  247 
Furthermore, we found that the SV2 glycan-binding residues are largely conserved in seven out 248 
of the eight BoNT/A subtypes (BoNT/A1-A3 and A5-A8) that have been identified up to date 249 
(Supplementary Fig. 9) 27. Notably, BoNT/A4 is the only one that has an Arg residue (R1292) 250 
at the equivalent position of BoNT/A1-G1292. Since BoNT/A1-G1292R mutant drastically 251 
decreases BoNT/A1 toxicity by blocking its binding to SV2 glycan (Figs. 4-5 and 252 
Supplementary Figs. 7-8) 21, we suggest that this is a major reason that causes the ~1,000-fold 253 
reduced biological activity of BoNT/A4 compared to BoNT/A1 28. Taken together, our findings 254 
suggest that BoNT/A1 and variants utilizes the genetically invariable carbohydrates as surrogate 255 
amino acids to engage the host receptors. Synergistic binding to two distinct cell surface 256 
receptors, SV2 (including its peptide and glycan moieties) and ganglioside, provides a plausible 257 
explanation for the extreme potency of BoNT/A and its remarkable specificity for nerve 258 
terminals (Fig. 6c). 259 
 260 
A new strategy for developing therapeutic antibodies against BoNT/A 261 
The novel glycan receptor for BoNT/A presents a promising target for developing toxin 262 
inhibitors. Remarkably, we found that a BoNT/A1-neutralizing human monoclonal antibody 263 
family CR2/CR1, which is currently in clinical trial 29,30, directly targets the glycan-binding site 264 
on HCA with its first antigen-binding loop of the light chain variable region occupying the 265 
glycan-binding site (Fig. 7a). The key epitopes for CR2/CR1 include precisely residues F953 266 
and H1064 29. Interestingly, residue F36 of CR2/CR1 uses a π-stacking interaction to bind 267 
BoNT/A1-H1064, mimicking its interactions with SV2C N559-glycan. CR2/CR1 also blocks 268 
binding of BoNT/A1 to bSV2C 21, but this is due to the large size of CR2/CR1 causing side-to-269 
side clash with bSV2C, as CR2/CR1 and bSV2C have non-overlapping binding sites on HCA 270 
(Fig. 7b-d). Together our data reveal that the strong neutralization potency of CR2/CR1 is 271 
empowered by simultaneously blocking BoNT/A1 binding to the glycan and peptide moieties of 272 
SV2.  273 
 274 
DISCUSSION 275 
Host cell-surface glycans are crucial for pathogen recognition. For example, influenza 276 
hemagglutinins use carbohydrates in determining the host range (e.g. swine, avian or human) 31. 277 
Our results reveal a novel host-recognition strategy, by which pathogens simultaneously 278 
recognize a protein segment and the neighboring glycans as a composite binding site. This 279 
unique strategy uses a conserved post-translational modification as an evolutionarily static 280 
recognition site, in addition to protein-protein interactions that encode the location and 281 
specificity information. Together, it provides a powerful solution to address the competing needs 282 
of achieving highly specific binding while also tolerating residue changes in receptors across 283 
multiple isoforms and species variants.  284 
Intriguingly, a similar strategy may be utilized by some important broad-neutralizing human 285 
antibodies, which are capable of neutralizing multiple serotypes of targeted viruses, such as 286 
dengue viruses and immunodeficiency virus-1 (HIV-1), by simultaneously recognizing the 287 
protein components and the highly conserved glycans on virus proteins 32-34. A similar model 288 
was also recently demonstrated for Notch1 receptor binding with its ligand Delta like 4 (DLL4) 289 
35, where DLL4 binds to the fucose and glucose at the base of an O-glycosylation site located 290 
within the protein-protein interface. Therefore, our findings offer an important strategy for 291 
engineering ligand-receptor interactions and broadly neutralizing antibodies for therapeutic 292 
applications. 293 
 294 
Accession codes. Atomic coordinates and structure factors for the HCA-bSV2C and HCA-gSV2C 295 
complexes will be deposited in the Protein Data Bank. 296 
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FIGURE LEGENDS 413 
 414 
Figure 1 SV2 glycosylation is critical for BoNT/A1 binding and entry into neurons. Lentivirus 415 
was used to infect mouse SV2A(-/-)SV2B(-/-) neurons to create neurons that express either the 416 
WT or the deglycosylation mutants of SV2A (a) or SV2C (b). Neurons were simultaneously 417 
exposed to BoNT/A1 (1 nM) and BoNT/D (0.1 nM) in a high K+ buffer for 5 minutes at 37°C. 418 
Unbound toxin was washed away, and the intoxicated cells were incubated for another 8 hour. 419 
Cell lysates were harvested and subjected to immunoblot analysis using mouse monoclonal 420 
antibodies against SNAP-25 (Cl 71.2), VAMP2 (Cl 69.1), and SV2 (pan-SV2). BoNT/D served 421 
as an internal control to confirm that SV2 mutants still sorted and localized correctly. Cleavage 422 
of SNAP-25 by BoNT/A1 generates a smaller fragment that is marked by an asterisk. Actin 423 
served as a loading control. 424 
Figure 2 Glycosylation in SV2 luminal domain enhances BoNT/A1 binding. (a) Sensorgrams of 425 
HCA binding to immobilized human bSV2C (blue) overlaid with a fit of 1:1 binding model 426 
(black). Since equilibrium binding was reached for all conditions tested, a steady state affinity 427 
was also determined (insert). (b) HCA binding to immobilized human gSV2C (red) was best fit to 428 
a heterogeneous binding model (black), whereas a 1:1 binding model was inapplicable 429 
(Supplementary Fig. 4). Insert: individual contributions of the two binding events observed in 430 
the heterogeneous interaction (blue and green). (c) Kinetic binding rates and affinities for HCA 431 
binding to human bSV2C or gSV2C. Shown values represent the mean ± S.D. (n = 2 for bSV2C, 432 
n = 3 for gSV2C). 433 
Figure 3 Structure of HCA in complex with human gSV2C. (a) Cartoon representation of the 434 
complex whereas HCA is gold and gSV2C is green. The black oval highlights the interacting β-435 
strands between them. gSV2C-N559 and the attached N-linked glycan are shown in the stick 436 
models. (b) A ~150° rotation of the complex about a vertical axis. (c-d) Close-up views of the 437 
protein-protein and protein-glycan association interfaces between HCA and gSV2C. HCA is in 438 
surface representation (gold), whereas HCA residues that directly interact with the peptide moiety 439 
of gSV2C or the N559 glycan are colored purple and light blue, respectively. Well-defined water 440 
molecules that mediate HCA-glycan binding are shown as green spheres. (e) Extensive 441 
interactions between gSV2C-N559 glycan and HCA. A schematic representation of the glycan 442 
structure is shown. The plots were generated using LIGPLOT 36. HCA and gSV2C residues are 443 
labeled brown and green, respectively. Hydrogen bonds are indicated by dashed green lines. Key 444 
hydrogen bonding distances are listed in Supplementary Table 1. Residues involved in 445 
hydrophobic interactions are represented by an arc with spokes radiating towards the binding 446 
partners they contact. 447 
Figure 4 Site-directed mutagenesis analysis of the SV2-binding site on HCA. (a-b) Binding of 448 
HCA variants (100 nM, 5 min, 37°C in a high K+ buffer) to rat hippocampal/cortical neurons was 449 
analyzed by immunostaining (panel a) or immunoblot (panel b). Scale bar, 20 μm. 450 
Synaptophysin (Syp) served as a loading control. (c-e) Binding of HCA variants (100 nM, 5 min) 451 
to neurons that express individual SV2A, 2B, or 2C was analyzed by immunoblot. 452 
Hippocampal/cortical neurons cultured from SV2A(+/+)SV2B(-/-) mice served as neurons that 453 
only express SV2A (panel c). Neurons that only express SV2B or SV2C were created by 454 
infecting neurons cultured from SV2A(-/-)SV2B(-/-) mice with lentiviruses that express SV2B 455 
(panel d) or SV2C (panel e). The results of immunostaining analysis are shown in 456 
Supplementary Fig. 8. 457 
 458 
Figure 5 Glycan binding-deficient BoNT/A1 displays drastic decreased neurotoxicity as 459 
examined by the mouse phrenic nerve (MPN) assay. BoNT/A1 F953R mutant showed no 460 
detectable toxicity even at the maximal concentration tested (200 nM), indicating a larger than 461 
106-fold reduction on toxicity. Shown are mean ± S.D. of 3-6 technical replicates. 462 
Figure 6 The SV2 glycan binding mode is conserved in BoNT/HA. (a) The SV2C glycan plays 463 
an indispensable role for HCHA binding as demonstrated by a pull-down assay using human 464 
bSV2C (with a SUMO tag) or gSV2C as baits. “Mu” is HCHA-F943G mutant. (b) The F943G 465 
mutation dramatically decreased HCHA binding to rat cortical neurons as analyzed by 466 
immunostaining and immunoblot. (c) Proposed model for simultaneous binding of BoNT/A1 to 467 
two neuronal surface receptors: glycosylated SV2 and ganglioside. GT1b is modeled based on 468 
the structure of a GT1b-bound HCA (PDB code 2VU9) 37. A representative complex type N-469 
linked glycan is modeled based on the structure of a glycan of human IgG1 (PDB code 3AVE) 470 
38. The glycan core that is observed in the HCA-gSV2C complex is colored green, whereas the 471 
remaining carbohydrates (mannose and NAG colored gray) could potentially extend to the N-472 
terminal sub-domain of HCA (HCNA). 473 
Figure 7 The SV2 glycan-binding site on BoNT/A1 is the target for the neutralizing antibody 474 
CR1. (a-b) BoNT/A1-neutralizing therapeutic antibody CR1 (PDB code: 2NYY) 29 occupies the 475 
SV2C glycan-binding site on HCA, but does not affect HCA’s SV2C peptide-binding site. An 476 
arrow in the schematic diagram indicates the side-to-side clash between SV2C and CR1. (c) A 477 
close-up view of the interface. gSV2C-N559 glycan (green), HCA-F953 and -H1064 (gold), 478 
residues 30-36 of CR1 ligand chain (LC, red), and residues 101-103 of CR1 heavy chain (HC, 479 
gray) are shown in stick models. (d) Residues of HCA that exclusively bind SV2C peptide, N559 480 
glycan or CR1 are colored in purple, green or cyan, respectively, while the HCA residues that are 481 
contacted by both N559 glycan and CR1 are in blue. 482 
483 
Table 1 Data collection and refinement statistics. 484 
 HCA-bSV2C (rat) HCA-gSV2C (human) 
Data collection   
Space group P 1 21 1 C 1 2 1 
Cell dimensions   
a, b, c (Å) 88.66, 143.99, 110.92 109.00, 111.85, 126.25 
α, β, γ  (°) 90, 93.6, 90 90, 101.3, 90 
Resolution (Å) 87.76-2.64 (2.73-2.64) 123.8-2.0 (2.03-2.00) 
Rmeas 0.172 (1.454) 0.159 (0.889) 
CC1/2 0.991 (0.599) 0.984 (0.722) 
I/σ(I) 9.1 (1.4) 6.7 (2.1) 
Completeness (%) 99.44 (99.20) 99.6 (99.9) 
Redundancy 3.4 (3.1) 2.9 (2.9) 
   
Refinement   
Resolution (Å) 87.76-2.64 123.81-2.00 
No. reflections 80,958 99,659 
Rwork/Rfree 0.239/0.271 0.176/0.216 
No. atoms   
     Protein 16,825 8,645 
     Ligand/ion - 128 
     Water 162 659 
B-factors   
     Protein 58.50 44.50 
     Ligand/ion - 58.70 
     Water 55.40 51.50 
r.m.s. deviations   
     Bond lengths (Å) 0.012 0.009 
     Bond angles (°) 1.22 1.01 
Statistics for the highest-resolution shell are shown in parentheses. 485 
  486 
METHODS 487 
Construct design and cloning. The gene of HCA (residues N872–L1296) was cloned into 488 
expression vector pQE30 with an N-terminal 6xHis-tag and a PreScission protease cleavage site. 489 
HCHA (residues E860–L1286) was cloned into pGEX-4T-2 vector that has a thrombin cleavage 490 
site following GST. The core region of human SV2C-L4 (residues V473–T567) was cloned into 491 
two different vectors: pET28a vector for E. coli expression and a pcDNA vector for mammalian 492 
cell expression. For E. coli expression, a 6xHis/SUMO (Saccharomyces cerevisiae Smt3p) tag 493 
was introduced to the N-terminus of SV2C-L4 to facilitate protein expression and purification 494 
(SUMO-bSV2C). For mammalian cell expression, a human IL2 signal sequence 495 
(MYRMQLLSCIALSLALVTNS), a 9xHis-tag, and a Factor Xa cleavage site were added to the 496 
N-terminus of SV2C-L4 (gSV2C). A second SV2C mammalian expression construct was made 497 
based on gSV2C by inserting SUMO between the Factor Xa site and SV2C (SUMO-gSV2C). 498 
Rat SV2C-L4 (residues P455–Y577) was covalently linked to the C-terminus of HCA through a 499 
peptide linker composed of a thrombin cleavage site (LVPRGS) and a PreScission protease 500 
cleavage site (LEVLFQGP). The covalently linked HCA-rbSV2C was cloned into pET28a vector 501 
with an N-terminal 6xHis-tag and a thrombin cleavage site. All HCA and HCHA mutations were 502 
generated using QuikChange site-directed mutagenesis (Agilent). All pH6tBoNTA mutants were 503 
prepared using the GeneTailor method (Invitrogen GmbH, Karlsruhe, Germany) employing 504 
suitable primers and pH6tBoNTA as template DNA 21. 505 
Protein expression and purification. HCA, HCHA, SUMO-bSV2C, and HCA-rbSV2C were 506 
expressed in E. coli strain BL21-Star (DE3) (Invitrogen). Bacteria were cultured at 37°C in LB 507 
medium containing appropriate selecting antibiotics. The temperature was reduced to 18°C when 508 
OD600 reached 0.4. Expression was induced with 0.2 mM IPTG (isopropyl-b-D-509 
thiogalactopyranoside) when OD600 reached 0.7, and continued at 18°C for ~16 hours. The cells 510 
were harvested by centrifugation and stored at -80°C until use. 511 
Wild-type and mutated recombinant full-length neurotoxin H6tBoNTA were produced under 512 
biosafety level 2 containment (project number GAA A/Z 40654/3/123) utilizing the E. coli strain 513 
M15pREP4 (Qiagen, Hilden, Germany) during 16 h of induction at 22°C in the presence of 0.2 514 
mM IPTG, and were purified on Co2+-Talon matrix (Takara Bio Europe S.A.S., France). Full-515 
length neurotoxins were eluted using 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 250 mM 516 
imidazole, subjected to size-exclusion chromatography (SEC; Superdex-200 16/60 column, GE 517 
Healthcare, Germany) in 100 mM Tris-HCl, pH 8.0, and 150 mM NaCl, frozen in liquid nitrogen 518 
and kept at -70°C. 519 
The His-tagged proteins (HCA, SUMO-bSV2C and HCA-rbSV2C) were purified using Ni2+-NTA 520 
(nitrilotriacetic acid, Qiagen, Hilden, Germany) affinity resins in a buffer containing 50 mM 521 
Tris, pH 8.0, 400 mM NaCl, and 40 mM imidazole. The proteins were eluted with a high-522 
imidazole buffer (50 mM Tris, pH 8.0, 400 mM NaCl, and 300 mM imidazole) and then dialyzed 523 
at 4°C against a buffer containing 20 mM HEPES, pH 7.5, and 150 mM NaCl. The His-tag of 524 
HCA and the His/SUMO-tag of SUMO-bSV2C were cleaved by PreScission and SUMO 525 
proteases, respectively. For the covalently linked HCA-rbSV2C, both thrombin and PreScission 526 
protease were used to cut the linker between the two proteins in order to avoid potential 527 
conformational constraint. GST-HCHA fusion protein was purified using glutathione Sepharose 528 
4B affinity resin (GE Healthcare) in a buffer containing 20 mM HEPES, pH 7.5, and 150 mM 529 
NaCl. HCHA was then released from the resins by on-column cleavage using thrombin. 530 
Tag-cleaved HCA and HCHA were further purified by MonoS ion-exchange chromatography 531 
(GE Healthcare) in a buffer containing 50 mM MES, pH 6.0, and eluted with a NaCl gradient. 532 
The peak fractions were then subjected to Superdex-200 SEC (GE Healthcare) in a buffer 533 
containing 20 mM sodium phosphate, pH 6.0, and 50 mM NaCl. SUMO-bSV2C (His/SUMO-tag 534 
cleaved or un-cleaved) and the cleaved HCA-rbSV2C were further purified by Superdex-200 535 
SEC in a buffer containing 20 mM HEPES, pH 7.5, and 150 mM NaCl. HCA-rbSV2C was 536 
concentrated to ~2 mg/ml for crystallization.  537 
SUMO-gSV2C and gSV2C were expressed and secreted from HEK 293 cells (BioLegend) and 538 
purified directly from cell culture media using Ni2+-NTA. The proteins were eluted from the 539 
resins with high concentration of imidazole and dialyzed against a buffer containing 50 mM Tris, 540 
pH 8.0, and 400 mM NaCl. gSV2C was then mixed with the purified HCA at a molar ratio of 541 
~1:2, and the HCA-gSV2C complex was isolated by Ni2+-NTA resins. After dialysis against a 542 
buffer containing 20 mM HEPES, pH 7.5, and 150 mM NaCl, the complex was further purified 543 
by Superdex-200 SEC using the same buffer. The complex was concentrated to ~10 mg/ml for 544 
crystallization. 545 
Crystallization. Initial crystallization screens were carried out using a Gryphon crystallization 546 
robot (Art Robbins Instruments) with high-throughput crystallization screening kits (Hampton 547 
Research and Qiagen). Extensive manual optimization was then performed at 20°C using the 548 
hanging-drop vapor-diffusion method when proteins were mixed with reservoir solutions in 1:1 549 
ratio. HCA-rbSV2C was initially crystallized in a condition containing 100 mM sodium 550 
cacodylate, pH 6.5, 13% polyethylene glycol (PEG) 3,350, and 200 mM NaCl. The best crystals 551 
were obtained in the presence of 0.7% (v/v) 1-butanol, which was identified using an additive 552 
screen kit (Hampton Research). The crystals were cryo-protected in the original mother liquor 553 
supplemented with 20% (v/v) glycerol and flash-frozen in liquid nitrogen. The HCA-gSV2C 554 
complex was originally crystallized as thin plates in a condition composed of 100 mM sodium 555 
acetate, pH 4.6, 20% PEG 3,350, and 200 mM ammonium phosphate monobasic. These crystals 556 
diffracted poorly. After extensive additive screening and optimization, the best crystals were 557 
obtained in the presence of 4% (w/v) polypropylene glycol P 400. The crystals were cryo-558 
protected in the reservoir solution supplemented with 20% (v/v) ethylene glycol and flash-frozen 559 
in liquid nitrogen.  560 
Data collection and structure determination. The X-ray diffraction data were collected at 100 561 
K at the NE-CAT beamline 24-ID, Advanced Photon Source (APS). The data were processed 562 
with XDS 39. The structure of HCA-rbSV2C was determined by molecular replacement software 563 
Phaser 40 using the structure of HCA (PDB code 3FUO) 10 as the search model. The structural 564 
model of rbSV2C was manually built, and the structural modeling and refinement were carried 565 
out iteratively using COOT 41 and Refmac from the CCP4 suite 42. This structure was later used 566 
as the search model to determine the structure of the HCA-gSV2C complex. All the refinement 567 
progress was monitored with the free R value using a 5% randomly selected test set 43. The 568 
structures were validated through the MolProbity web server 44 and showed excellent 569 
stereochemistry. Data collection and structural refinement statistics are listed in Table 1. All 570 
structure figures were prepared with PyMol (http://www.pymol.org). 571 
Pull-down assay. The pull-down assay was performed using Ni2+-NTA resins in 1 ml buffer 572 
containing 50 mM Tris, pH 8.0, 400 mM NaCl, 10 mM imidazole, and 0.1% Tween-20. SUMO-573 
bSV2C or gSV2C served as the bait while HCA or HCHA variants were the preys. SV2C was 574 
pre-incubated with Ni2+-NTA resins at 4°C for 1 hour, and the unbound protein was washed 575 
away. The resins were then divided into small aliquots (~ 5μg of bait) and mixed with the preys 576 
(~ 30 μg). The pull-down assay was carried out at 4°C for ~1.5 hours. The resins were washed 577 
twice, and the bound proteins were released from resins using 300 mM imidazole. 578 
Protein melting assay. The thermal stability of HCA or HCHA variants was measured using a 579 
fluorescence-based thermal shift assay on a StepOne real-time PCR machine (Life 580 
Technologies). The protein (~5 μM) was mixed with the fluorescent dye SYPRO Orange 581 
(Sigma-Aldrich) immediately before the experiment. The samples were heated from 25°C to 582 
90°C in ~ 45 min. The midpoint of the protein-melting curve (Tm) was determined using the 583 
analysis software provided by the instrument manufacturer. The data obtained from three 584 
independent experiments were averaged to generate the bar graph. 585 
Surface plasmon resonance (SPR). Binding kinetics and affinity were determined on a Biacore 586 
X100 unit (GE Healthcare) at 25°C using HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 587 
mM EDTA, 0.05% Tween-20) as running buffer at a flow rate of 30 μL/min. Using standard 588 
EDC/NHS amine coupling chemistry, SUMO-gSV2C or SUMO-bSV2C were coupled on flow 589 
cell (Fc) 2 of a CM5 sensor chip (GE Healthcare) to a surface density of ~83 resonance units 590 
(RUs) or ~105 RUs, respectively. Control Fc1 was blank immobilized by EDC/NHS activation 591 
before blocking with 1 M ethanolamine (GE Healthcare).  592 
For kinetic measurements, HCA was injected in 1:3 dilution series ranging from 1,200 nM to 593 
4.94 nM for gSV2C or 2,000 nM to 2.74 nM for bSV2C. Each measurement was started and 594 
ended with injection of the highest analyte concentration to ensure retained binding capacity. 595 
Association was monitored for 120 seconds by analyte injection followed by 300 second 596 
injections of running buffer to monitor binding dissociation. Between measurements, the surface 597 
was regenerated by 60 second injections of 10 mM glycine-HCl (pH 1.7) at 10 μL/min. Binding 598 
kinetics were determined by fitting the double referenced 45 binding curves using the 599 
heterogeneous (gSV2C) or the 1:1 Langmuir binding models (bSV2C) with global Rmax and RI 600 
set to zero (Biacore Evaluation Software 2.01). Due to the highly transient interaction of HCA 601 
with bSV2C, equilibrium binding was reached for all HCA concentrations tested. Therefore, 602 
steady state affinity was determined for bSV2C by fitting a four-parametric Hill equation to the 603 
binding responses 65 seconds after analyte injection over log-transformed HCA-concentrations 604 
using Prism 5.04 (GraphPad) with bottom constraint set to zero. The good agreement between 605 
the binding affinity determined by kinetic analysis and the steady state affinity proved that 606 
kinetic binding rates for bSV2C were reliable despite being close to the measurement limits of 607 
the instrument. Kinetic binding rates were determined by n = 2 (bSV2C) or n = 3 (gSV2C) 608 
independent experiments. Shown values represent the mean ± standard deviation. 609 
To compare the interaction of HCA WT and its mutants with bSV2C (511 RUs) and separately 610 
with gSV2C (479 RUs), the reactions were performed in the “interactive manual run mode”. The 611 
HCA variants were injected at concentrations of 0.01, 1.0, 10, 25, 50, 75, 100 and 200 nM, each 612 
in triplicate, and at a flow-rate of 10 μL/min. The chip surface was regenerated by two injections 613 
of glycine-HCl (10 mM, pH 2.0, 30 sec contact time) allowing the removal of the analyte 614 
without changing the activity of the immobilized ligand. This was confirmed by the equal 615 
responses obtained from the binding assays before and after regeneration. Results were plotted as 616 
response (RU) versus concentration of HCA using Prism 6 (GraphPad Software Inc., La Jolla, 617 
CA). 618 
Cell biology materials and constructs. SV2A and SV2B knockout mice were obtained from the 619 
Jackson Laboratory. Rat cDNAs encoding SV2A, SV2B, and SV2C were generously provided 620 
by R. Janz (Houston, TX). They were cloned into a lentiviral vector (Lox-Syn-Syn) as we 621 
previously described 8. This vector contains two separate neuronal-specific synapsin promoters. 622 
One promoter drives expression of SV2 and the other one drives expression of GFP as a marker. 623 
Human cDNA encoding SV2C was obtained from PlasmID repository of Harvard Medical 624 
School. Human monoclonal antibody against HCA (RAZ-1) was generously provided by J. 625 
Marks (San Francisco, CA). Mouse monoclonal antibodies against VAMP2 (Cl 69.1), SNAP-25 626 
(Cl 71.2), SV2 (pan-SV2), Syp (Cl 7.2) were generously provided by E. Chapman (Madison, 627 
WI) and are available from Synaptic Systems (Göttingen, Germany). The following antibodies 628 
were purchased from indicated vendors: mouse monoclonal antibody against actin (Sigma); 629 
rabbit polyclonal antibody against synapsin (Millipore); rabbit polyclonal antibody against GFP 630 
(Abcam). Purified BoNT/A1 of Hall-A strain and BoNT/D of D1873 strain were generously 631 
provided by E. Johnson (Madison, WI).  632 
Neuron culture and lentivirus transduction. Rat hippocampal/cortical neurons were prepared 633 
from E18-19 embryos. Mouse SV2A/B double knockout neurons were prepared from postnatal 634 
day 1 pups as previously described 8. Dissected hippocampi and cortex were dissociated with 635 
papain following manufacture instructions (Worthington Biochemical, NJ). Cells were plated on 636 
poly-D-lysine coated coverslips. Experiments were carried out generally using DIV (days in 637 
vitro) 13-15 neurons. Lentivirus were prepared as described previously using HEK293FT cells 8. 638 
Viruses were added to neurons at DIV5.  639 
HCA and HCHA binding to neurons. Neurons were exposed to 100 nM HCA or HCHA in high 640 
K+ buffer, which contains (mM): NaCl 140, KCl 3, KH2PO4 1.5, Na2HPO4 8, MgCl2 0.5, and 641 
CaCl2 1, for 5 minutes at 37°C. Cells were then washed three times with phosphate-buffered 642 
saline (PBS). Binding of HCA or HCHA was examined using two complementary approaches. (1) 643 
Immunostaining: neurons were fixed with 4% paraformaldehyde and permeabilized with 0.3% 644 
Triton X-100 in PBS solution. Images were collected using a Leica TCS SP8 confocal 645 
microscope with a 40X oil objective. (2) Immunoblot analysis: neurons were harvested in a lysis 646 
buffer (PBS with 1% Triton X-100, 0.05% SDS and protease inhibitor cocktail (Roche, CA), 100 647 
μl per one well of 24-well plates). Lysates were centrifuged for 10 minutes at 4 C and the 648 
supernatants were subjected to SDS-PAGE and western blot analysis. Binding of HCA or HCHA 649 
were detected using a monoclonal human anti-HCA antibody (RAZ-1), which recognizes both 650 
HCA and HCHA. It also recognizes mutants of HCA and HCHA examined in this study with 651 
similar sensitivity (“input” lanes in Figs. 4b and 6b) 652 
Entry of BoNTs into neurons. Neurons were exposed to 1 nM BoNT/A1 and 0.1 nM BoNT/D 653 
in high K+ buffer for 5 minutes at 37°C. Cells were washed three times with PBS and further 654 
incubated in toxin-free media for 8 hrs. Neuron lysates were then harvested and subjected to 655 
immunoblot analysis, detecting cleavage of toxin substrate SNAP-25 (for BoNT/A1) and 656 
VAMP2 (for BoNT/D). Cleavage of SNAP-25 by BoNT/A1 generates a smaller fragment that 657 
can be detected on immunoblot. Cleavage of VAMP2 by BoNT/D resulted in a loss of 658 
immunoblot signal of VAMP2.  659 
Mouse phrenic nerve hemidiaphragm (MPN) assay. The MPN assay was performed as 660 
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Supplementary Figure 1  
SV2 has a unique structure.  
(a) The structure of human gSV2C displays a unique pentapeptide-repeat motif, where 
phenylalanine residues, except S527, spaced 5 residues apart provide important stacking effect to 
stabilize the structure. These residues are shown in sticks, with the ones that are conserved in all 
three SV2 isoforms across different species are colored gold. (b) The structures of HCA in 
complex with the rat bSV2C or human gSV2C are superimposed. The N559 glycan of gSV2C is 
shown as a transparent sphere model. Residue F563 of human SV2C is replaced by L563 in rat 
SV2C, which abolishes the cation-π stacking interaction. (c) Representative sequences of SV2A, 
SV2B, and SV2C were selected from different species: human SV2A (NP_055664.3), 2B 
(CAG33367.1), 2C (AAI00828.1); rat SV2A (NP_476558.2), 2B (NP_476555.1), 2C 
(NP_113781.1); dog SV2A (XP_003639668.1), 2B (XP_005618386.1), 2C (XP_546060.2); 
bovine SV2A (NP_776387.1), 2B (NP_001076917.1), 2C (NP_001178948.1); chicken SV2B 
(XP_425081.2), 2C (XP_429151.3). Sequence alignments were made using Clustal Omega 1 and 
ESPript 2. Only the truncated loop 4 of SV2 is shown for clarity. Identical residues are indicated 
with white letters on a red background, similar conserved residues are in red letters, varied 
residues are in black letters. The residues of SV2C that directly bind to HCA are indicated by 
blue ovals; the pentapeptide-repeat is labeled by green triangles. The N-linked glycosylation site, 






Supplementary Figure 2 
The protein-protein interactions between HCA and the human gSV2C.  
The plots were generated using LIGPLOT 3. BoNT/A and SV2C residues are labeled brown and 
green, respectively. Hydrogen bonds are indicated by dashed green lines. A similar interaction 
network is observed in the structure of HCA in complex with the rat bSV2C, except that the 








Supplementary Figure 3 
Expression levels of the deglycosylation mutants of SV2A, 2B, and 2C in neurons. 
Hippocampal/cortical neurons cultured from SV2A(-/-)SV2B(-/-) mice were infected with 
lentiviruses that express either WT SV2A, 2B, and 2C, or indicated deglycosylation mutants. 
Cell lysates were harvested and subjected to immunoblot analysis. Actin served as a loading 
control. The lentiviral vector contains two separated synapsin promoters, with one driving 
expression of SV2 and the other driving expression of GFP. Thus, GFP served as an internal 
control for viral infection. Immunoblot signals of SV2 were quantified, normalized using GFP 
signals, and compared between WT and deglycosylation mutants. The same amounts of viruses 
were used for WT SV2A and SV2A-N573A (panel a), and for WT SV2C and SV2C-N559A 
(panel c). The deglycosylation mutation has no effect on SV2A and modestly reduced the 
expression level of SV2C in neurons. However, it severely reduced the expression level of 
SV2B. As shown in panel b, even with 10-fold more viruses, SV2B-N516A expression was still 









Supplementary Figure 4 
SPR binding curves of HCA and gSV2C (red) overlaid with a 1:1 Langmuir binding model fit 









Supplementary Figure 5 
Electron densities of the N559 glycan of SV2C in the gSV2C-HCA complex.  
(a) Key glycan-binding residues of HCA and the N559 glycan are shown as stick models. Water 
molecules facilitating the HCA-glycan association are shown as green spheres. A simulated-
annealing omit electron density map contoured at 1.5 σ was overlaid with the final refined 








Supplementary Figure 6 
Single-site mutations of HCA and HCHA adopt wild-type-like structures.  
The thermal stability of proteins was measured using a fluorescence-based thermal shift assay on 
a StepOne real-time PCR system (ThermoFisher) 4. Specifically, protein melting was monitored 
using a hydrophobic dye, SYPRO Orange (Sigma-Aldrich), as the temperature was increased in 
a linear ramp from 20oC to 95oC. The midpoint of the protein-melting curve (Tm) was 
determined using the software provided by the instrument manufacturer. The data are presented 
as mean ± S.D., n = 3. All HCA and HCHA mutants showed Tm values comparable to the wild-









Supplementary Figure 7 
Characterization of bindings between HCA variants and human bSV2C and gSV2C, respectively.  
(a) Surface plasmon resonance was used to examine the changes of binding affinity between 
HCA variants and SUMO-bSV2C or gSV2C, respectively. SV2C was covalently immobilized to 
a CM5 chip as a ligand whereas HCA variants were analytes. Bars from left to right represent the 
responses when HCA was applied at 10 pM, 1 nM, 10 nM, 25 nM, 50 nM, 75 nM, 100 nM, and 
200 nM, respectively. RU stands for arbitrary response unit. (b-c) Interactions between HCA 
variants (preys) and SUMO-bSV2C or gSV2C (baits) were examined by a pull down assay. (d-f) 
Binding kinetics and affinity between HCA-F953G and immobilized bSV2C (107 RU; panel d) 
or gSV2C (74 RU; panel e) were determined by injecting 1:3 dilution series ranging from 2,000 







Supplementary Figure 8 
Binding of glycan-binding deficient HCA mutants to neurons that express individual SV2 
isoforms.  
Hippocampal/cortical neurons cultured from SV2A(+/+)SV2B(-/-) mice served as neurons that 
only express SV2A. Neurons that only express SV2B or SV2C were created by infecting neurons 
cultured from SV2A(-/-)SV2B(-/-) mice with lentiviruses that express SV2B or SV2C, 
respectively. Neurons were then exposed to WT or indicated HCA mutant (100 nM, 5 min), 
washed, fixed, and subjected to immunostaining analysis. HCA was detected with a monoclonal 
human anti-BoNT/A antibody (RAZ-1) and SV2 was detected with a mouse monoclonal pan-











Supplementary Figure 9 
 
Sequence alignment among eight BoNT/A subtypes and BoNT/HA.  
 
The amino acid sequence of BoNT/A1-A8 and HA are taken from GenBank: AAQ06331.1 (A1), 
ACO83782.1 (A2), ABA29017.1 (A3), ACQ51417.1 (A4), ACG50065.1 (A5), ACW83608.1 
(A6), AFV13854.1 (A7), AJA05787.1 (A8), and KGO15617.1 (HA). Sequence alignments were 
made using Clustal Omega 1 and ESPript 2. Identical residues are indicated with white letters on 
a red background, similar conserved residues are in red letters, varied residues are in black 
letters. Key HCA residues that are recognized by antibody CR1 (PDB code: 2NYY) 
5 are 
indicated by black stars. HCA residues that directly interact with SV2C peptide or the N559-





Supplementary Table 1 
 
Water-mediated interactions in the SV2C glycan-HCA interface 
 
Water # Distance (Å) Water # SV2C N559-glycan HCA (or SV2C) 
W1 3.15 W2   
 3.04   F953 [N] 
 3.04   N954 [N] 
 2.79   S957 [OG] 
 2.97   D1062 [OD2] 
W2 2.90  NAG603 [O7]  
 2.67   D1062 [OD2] 
 2.76   R1065 [NH2] 
W3 2.62  NAG603 [O3]  
 3.15  BMA604 [O6]  
 2.77   H1064 [O] 
W4 2.84  FUC601 [O2]  
 3.39  NAG602 [O6]  
 2.70  NAG603 [N2]  
 2.66   D1289 [O] 
W5 2.61  FUC601 [O2]  
 3.40  FUC601 [O3]  
 2.69   D1289 [OD1] 
W6 2.79 W7   
 2.66   Y1155 [OH] 
 2.84   D1288 [O] 
 3.02   G1292 [N] 
W7 2.84  FUC601 [O4]  
 3.38  FUC601 [O5]  
 2.60   E1293 [O] 
W8 3.32  NAG602 [O7]  
 2.80   D539 [OD2] – SV2C 
W9 2.95 W10   
 2.96   F953 [O] 
 2.67   T1145 [OG1] 
 3.12   N559 [OD1] – SV2C 
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